Cargando…

496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment

BACKGROUND: Recurrent Clostridium difficile infection (CDI) is associated with significant morbidity, mortality and healthcare related costs. Up to 30% of CDI cases recur, resulting in 83,000 cases of recurrent CDI per year. Although agents for primary and secondary prophylaxis for CDI including the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampson, Mindy, Zeitler, Kristen, Marcelin, Jasmine R, Aslam, Sadaf, Sinnott, John, Lakshmi, Seetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253572/
http://dx.doi.org/10.1093/ofid/ofy210.505
_version_ 1783373526711926784
author Sampson, Mindy
Zeitler, Kristen
Marcelin, Jasmine R
Aslam, Sadaf
Sinnott, John
Lakshmi, Seetha
author_facet Sampson, Mindy
Zeitler, Kristen
Marcelin, Jasmine R
Aslam, Sadaf
Sinnott, John
Lakshmi, Seetha
author_sort Sampson, Mindy
collection PubMed
description BACKGROUND: Recurrent Clostridium difficile infection (CDI) is associated with significant morbidity, mortality and healthcare related costs. Up to 30% of CDI cases recur, resulting in 83,000 cases of recurrent CDI per year. Although agents for primary and secondary prophylaxis for CDI including the use of probiotics, antibiotics, fecal microbiota transplantations, and newer therapies such as bezlotoxumab have been reported, there is no consensus guidelines regarding their use. The purpose of this study was to assess physician practices regarding secondary prophylaxis for CDI. METHODS: This cross-sectional study using Qualtrics electronic survey (24 questions) assessed physician practice preferences. The survey was distributed through institutional emails and through the Infectious Disease Society of America “IDea Exchange” forum. Responses were collected and analyzed using descriptive statistics. RESULTS: A total of 246 surveys were completed. Physicians were surveyed from greater than 100 locations (see Figure 1). Most (229, 93%) of the physicians practiced in an inpatient setting. Respondent specialties were primarily infectious diseases (138, 56%) followed by internal medicine (72, 29%). Most physicians (173, 71%) use secondary prophylaxis for CDI prevention (see Figure 2). Vancomycin (121, 70%) and probiotics (114, 66%) were most commonly used for CDI secondary prophylaxis, (see Figure 3). Of 164 physicians who used secondary prophylaxis half of them (89, 54.2%), used prophylaxis only for patients with a history of recurrent CDI receiving antibiotics and about a third, (49, 29.9%) utilized it for patients with a history of CDI who were receiving antibiotics. ID physicians were more likely to prescribe secondary prophylaxis as compared with non-ID physicians (85% of 127 respondents vs. 75% of 85 respondents, P = 0.052). The use of secondary prophylaxis was similar among private practice and academic physicians (84% of 39 vs. 80% of 157 respondents, P = 0.591). CONCLUSION: The majority of the physicians who responded to this survey use secondary prophylaxis to prevent recurrent CDI, hence future CDI guidelines need to address the role of secondary prophylaxis in clinical practice. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253572
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62535722018-11-28 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment Sampson, Mindy Zeitler, Kristen Marcelin, Jasmine R Aslam, Sadaf Sinnott, John Lakshmi, Seetha Open Forum Infect Dis Abstracts BACKGROUND: Recurrent Clostridium difficile infection (CDI) is associated with significant morbidity, mortality and healthcare related costs. Up to 30% of CDI cases recur, resulting in 83,000 cases of recurrent CDI per year. Although agents for primary and secondary prophylaxis for CDI including the use of probiotics, antibiotics, fecal microbiota transplantations, and newer therapies such as bezlotoxumab have been reported, there is no consensus guidelines regarding their use. The purpose of this study was to assess physician practices regarding secondary prophylaxis for CDI. METHODS: This cross-sectional study using Qualtrics electronic survey (24 questions) assessed physician practice preferences. The survey was distributed through institutional emails and through the Infectious Disease Society of America “IDea Exchange” forum. Responses were collected and analyzed using descriptive statistics. RESULTS: A total of 246 surveys were completed. Physicians were surveyed from greater than 100 locations (see Figure 1). Most (229, 93%) of the physicians practiced in an inpatient setting. Respondent specialties were primarily infectious diseases (138, 56%) followed by internal medicine (72, 29%). Most physicians (173, 71%) use secondary prophylaxis for CDI prevention (see Figure 2). Vancomycin (121, 70%) and probiotics (114, 66%) were most commonly used for CDI secondary prophylaxis, (see Figure 3). Of 164 physicians who used secondary prophylaxis half of them (89, 54.2%), used prophylaxis only for patients with a history of recurrent CDI receiving antibiotics and about a third, (49, 29.9%) utilized it for patients with a history of CDI who were receiving antibiotics. ID physicians were more likely to prescribe secondary prophylaxis as compared with non-ID physicians (85% of 127 respondents vs. 75% of 85 respondents, P = 0.052). The use of secondary prophylaxis was similar among private practice and academic physicians (84% of 39 vs. 80% of 157 respondents, P = 0.591). CONCLUSION: The majority of the physicians who responded to this survey use secondary prophylaxis to prevent recurrent CDI, hence future CDI guidelines need to address the role of secondary prophylaxis in clinical practice. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253572/ http://dx.doi.org/10.1093/ofid/ofy210.505 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Sampson, Mindy
Zeitler, Kristen
Marcelin, Jasmine R
Aslam, Sadaf
Sinnott, John
Lakshmi, Seetha
496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title_full 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title_fullStr 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title_full_unstemmed 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title_short 496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
title_sort 496. secondary prophylaxis for clostridium difficile infection: a physician practice assessment
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253572/
http://dx.doi.org/10.1093/ofid/ofy210.505
work_keys_str_mv AT sampsonmindy 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment
AT zeitlerkristen 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment
AT marcelinjasminer 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment
AT aslamsadaf 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment
AT sinnottjohn 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment
AT lakshmiseetha 496secondaryprophylaxisforclostridiumdifficileinfectionaphysicianpracticeassessment